Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells, directed at Tumor neoantigens (patient tumor antigens) · developed by Nektar Therapeutics
C-TIL051 is a preparation of autologous tumor-infiltrating lymphocytes derived from each patient's resected tumor and expanded ex vivo. After administration back into the patient, the cells recognize and kill the patient's tumor cells. It is studied in metastatic non-small cell lung cancer, in combination with IL-15 (NKTR-255) and pembrolizumab.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05676749 | Phase 1 | Metastatic Non Small Cell Lung Cancer | Terminated | NKTR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Metastatic Non Small Cell Lung Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the NKTR page.
See NKTR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NKTR catalysts and pipeline →